DR. MICHAEL Y. ASHIGBI, M.D.

TYLER, TX

Research Active
Internal Medicine - Hematology & Oncology NPI registered 21+ years 1 publication 1995 – 1995 NPI: 1649275355
Internal Medicine - Hematology & Oncology
Acute DiseaseTumor Cells, CulturedAntigens, CDDexamethasoneAntigens, CD34CyclosporineLeukemia, MyeloidRhodaminesDrug Resistance, MultipleATP Binding Cassette Transporter, Subfamily B, Member 1Verapamil

Practice Location

721 CLINIC DR
TYLER, TX 75701-2043

Phone: (903) 592-6152

What does MICHAEL ASHIGBI research?

Dr. Ashigbi studies acute myeloid leukemia, a type of cancer that affects the blood and bone marrow. His research primarily focuses on finding effective treatments for patients who experience drug resistance, a situation where cancer cells no longer respond to the medications typically used to treat them. By testing various agents, he aims to understand which patients respond best to specific treatments, thereby personalizing care and improving survival rates.

Key findings

  • In his study, verapamil and cyclosporine A completely reversed drug resistance in samples from 23 out of 56 patients with acute myeloid leukemia.
  • In contrast, high doses of these drugs did not work at all in 17 patients, highlighting that drug efficacy varies widely among individuals.
  • The variability in treatment response indicates the need for tailored approaches in managing acute myeloid leukemia.

Frequently asked questions

Does Dr. Ashigbi study acute myeloid leukemia?
Yes, Dr. Ashigbi specifically studies acute myeloid leukemia and how to effectively treat it.
What treatments has Dr. Ashigbi researched?
He has researched the effectiveness of the drugs verapamil and cyclosporine A in overcoming drug resistance in leukemia.
Is Dr. Ashigbi's work relevant to patients with drug-resistant leukemia?
Absolutely, his findings directly target improving treatment strategies for patients who experience drug resistance in acute myeloid leukemia.

Publications in plain English

Modulation of multidrug resistance in de novo adult acute myeloid leukemia: variable efficacy of reverting agents in vitro. Eastern Cooperative Oncology Group.

1995

Blood reviews

Paietta E, Andersen J, Racevskis J, Ashigbi M, Cassileth P +1 more

Plain English
This study looked at how well two drugs, verapamil and cyclosporine A, can help overcome drug resistance in patients with a type of leukemia called acute myeloid leukemia (AML). Researchers tested samples from 56 patients and found that in 23 of them, the drugs completely stopped the resistance mechanism, while in 17 patients, even high doses did not work at all. These findings are important because they show that the effectiveness of these drugs varies widely between patients, which can impact treatment strategies. Who this helps: This helps doctors determine more effective treatment options for patients with acute myeloid leukemia.

PubMed

Frequent Co-Authors

E Paietta J Andersen J Racevskis P Cassileth P H Wiernik

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.